<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368355</url>
  </required_header>
  <id_info>
    <org_study_id>H-8701-MOHEL</org_study_id>
    <nct_id>NCT00368355</nct_id>
  </id_info>
  <brief_title>T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts</brief_title>
  <acronym>MOHEL</acronym>
  <official_title>CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects are being asked to participate in this study because treatment of their disease
      requires them to receive a stem cell transplant. Stem cells or &quot;mother&quot; cells are the source
      of normal blood cells and lead to recovery of blood counts after bone marrow transplantation
      (BMT). Unfortunately, there is not a perfectly matched stem cell donor (like a sister or
      brother) and the subject's disease is considered rapidly progressive and does not permit
      enough time to identify another donor (like someone from a registry list that is not their
      relative). We have, however, identified a close relative of the subject's whose stem cells
      are not a perfect match, but can be used. However, with this type of donor, there is
      typically an increased risk of developing graft-versus-host disease (GVHD), a high rate of
      transplant failure, and a longer delay in the recovery of the immune system.

      GVHD is a serious and sometimes fatal side effect of stem cell transplant. GVHD occurs when
      the new donor cells (graft) recognizes that the body tissues of the patient (host) are
      different from those of the donor. When this happens, cells in the graft may attack the host
      organs, primarily the skin, liver, and intestines. The number of occurrences and harshness of
      severe GVHD depends on several factors, including the degree of genetic differences between
      the donor and recipient, the intensity of the pre-treatment conditioning regimen, the
      quantity of transplanted cells, and the recipient's age. In recipients of mismatched family
      member or matched unrelated donor stem cell transplants, there is a greater risk of GVHD so
      that 70-90% of recipients of unchanged marrow will develop severe GVHD which could include
      symptoms such as marked diarrhea, liver failure, or even death.

      In an effort to lower the occurrences and severity of graft-versus-host disease in patients
      and to lower the rate of transplant failure, we would like to specially treat the donor's
      blood cells to remove cells that are most likely to attack the patient's tissues. This will
      occur in combination with intense conditioning treatment that the patient will receive before
      the transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To participate in this study, the subject will need to have a central line (a thin plastic
      catheter or tube that is placed during surgery into one of the large veins in the neck or
      chest).

      Also before treatment can begin, we will test the subject's blood for viruses which can cause
      problems after the transplant.

      Before treatment can begin, stem cells will be collected from the donor that has been
      selected as the best match for the subject. White blood cells will be collected from the
      donor. The cells will then be mixed with a special protein called a CD34 antibody that binds
      to the stem cells which will then be separated out from the white blood cells by a special
      machine called a CLINIMACs CD34 Reagent System in the laboratory. This is an investigational
      and experimental device which is not approved by the FDA. Although this device is not
      approved for use in this country, it has been in use for years and is approved in other
      countries. The stem cells will be collected and frozen before we start to give chemotherapy.

      TREATMENT PLAN

      To prepare the subject's body for transplantation, the subject will be given high dose
      chemotherapy (also called a conditioning treatment) for 8 days prior to the transplant as
      follows:

      The subject will be given a drug called Ara-C in high doses through the central line every 12
      hours starting 8 days before transplant (called day - 8) until 5 days before transplant
      (called day - 5). Starting one day after receiving the first Ara-C dose (day - 7), we will
      add a drug called cyclophosphamide once a day to the treatment for the next two days. This
      will be given in high doses (also through the central line). Also on day - 7, we will add a
      drug called MESNA. MESNA is used to decrease the side effects caused by cyclophosphamide.
      After the medication treatment is finished (day - 4), radiation treatment will be given to
      the entire body twice a day for 4 days. The chemotherapy and radiation treatment will last 8
      days. If the subject has abnormal cells in the spinal fluid, 6 extra daily doses of radiation
      treatment may be given to the head. This would be done before any of the drugs are given and
      before the subject is admitted for transplant.

      NOTE: Depending on the subjects health status, the doctor may decide the subject should not
      receive Ara-C. If this is a possibility, the doctor will discuss this with the subject.

      On the second day of radiation (day -3), the subject will receive CAMPATH-1H as a daily
      4-hour IV (intravenous, by vein). The subject will receive this infusion once a day for a
      total of three days. CAMPATH 1H is a special type of protein called an antibody, that works
      against certain types of blood cells. CAMPATH 1H is important because it stays active in the
      body for a long time after infusion, which means it may work longer at preventing GVHD
      symptoms.

      The day after the radiation treatment is completed (day 0), the subject will receive the
      specially selected donor stem cells. Once in the bloodstream, the cells will go to the bone
      marrow and should begin to grow. If the subject is at risk for developing GVHD or if the
      subject begins to develop GVHD, the doctor will prescribe medicines to help prevent or treat
      this side effect. The doctor will describe these medicines at that time.

      To learn more about the way the new cells are growing blood will be taken for research
      purposes at approximately 3 months, 6 months, 9 months, and a year after the transplant. On
      day 100, the subject will have the same tests/evaluations the subject has been experiencing
      since the transplant, however, the subject will also have a bone marrow aspirate (we take a
      sample of bone marrow to evaluate the disease and GVHD status). For patients who do not
      develop GVHD, they may have an additional bone marrow aspirate on day 180 (about 2 months
      after the previous one).

      After day 365, the subject will be asked to return to the clinic once a year for evaluations.
      These evaluations will be similar to the ones the subject had on day 100.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment Rate After Transplant</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of participants with hematopoietic engraftment post-transplant. Engraftment is defined as the first day absolute neutrophil counts exceeded 0.5 X 10^9/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Post BMT Toxicities</measure>
    <time_frame>100 Days</time_frame>
    <description>Number of participants who experience organ failure or severe infections (defined as Grade III/IV by NCI CTC for Adverse Events (CTCAE), version 2.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe GVHD Rate</measure>
    <time_frame>100 Days</time_frame>
    <description>Percentage of participants with Grade III/IV acute GVHD. Severe GVHD is defined as Grade III/IV acute GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Acute GVHD</measure>
    <time_frame>First 100 Days</time_frame>
    <description>Number of participants with acute GVHD graded by the method of Przepiorka et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Chronic GVHD</measure>
    <time_frame>Up to 1 Year</time_frame>
    <description>Number of participants with chronic GVHD graded by the method of Przepiorka et al, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>1 Year</time_frame>
    <description>To evaluate the effect of T-cell depletion by positive selection for CD34 on immune reconstitution, which will be determined from total lymphocyte count, from T and B cell numbers and from T cell subset analyses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of Remission in Patients</measure>
    <time_frame>1 Year</time_frame>
    <description>Median length of remission in patients with high risk leukemia treated with myeloablative chemotherapy, radiotherapy and CD34 selected peripheral blood stem cells from haploidentical related donors using Kaplan-Meier method</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Non Hodgkins Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Hemophagocytic Lymphohistiocytosis (HLH)</condition>
  <condition>Familial Hemophagocytic Lymphohistiocytosis (FLH)</condition>
  <condition>Viral-associated Hemophagocytic Syndrome (VAHS)</condition>
  <condition>X-linked Lymphoproliferative Disease (XLP)</condition>
  <arm_group>
    <arm_group_label>CLINIMACS Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISOLEX Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>day-8 through day-5
3 g/m2 q 12 hours</description>
    <arm_group_label>CLINIMACS Device</arm_group_label>
    <arm_group_label>ISOLEX Device</arm_group_label>
    <other_name>cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>day-7 and day-6
45 mg/kg</description>
    <arm_group_label>CLINIMACS Device</arm_group_label>
    <arm_group_label>ISOLEX Device</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Campath-1H</intervention_name>
    <description>day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS</description>
    <arm_group_label>CLINIMACS Device</arm_group_label>
    <arm_group_label>ISOLEX Device</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>day-4 through day-1
175 cGy x 2 at 24 cGy/min</description>
    <arm_group_label>CLINIMACS Device</arm_group_label>
    <arm_group_label>ISOLEX Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <description>Stem cells are infused on day 0</description>
    <arm_group_label>CLINIMACS Device</arm_group_label>
    <arm_group_label>ISOLEX Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Lack of suitable conventional donor (i.e. 5/6 or 6/6 related or 5/6 or 6/6 unrelated
             donor) or presence of a rapidly progressive disease not permitting time to identify an
             unrelated donor

          -  Age less than or equal to 55 years of age

          -  Patients with high risk ALL in CR1 or ALL or high grade (stage III or IV) NHL after
             first relapse or with primary refractory disease or minimal residual diseases.

          -  Myelodysplastic syndrome

          -  Patients with high risk AML in CR1 or after first relapse or with primary refractory
             disease or minimal residual disease.

          -  CML

          -  Hemophagocytic lymphohistiocytosis (HLH), familial hemophagocytic lymphohistiocytosis
             (FLH), viral-associated hemophagocytic syndrome (VAHS), X-linked lymphoproliferative
             disease (XLP), Severe chronic active Epstein Barr virus infection (SCAEBV) with
             predilection for T- or NK-cell malignancy

          -  Donor cells should be collected and frozen before conditioning starts

        EXCLUSION CRITERIA:

          -  Patients with a life expectancy (&lt; / = 6 weeks) limited by diseases other than
             leukemia

          -  Patients with symptomatic cardiac disease, or evidence of significant cardiac disease
             by echocardiogram (i.e., shortening fraction &lt; 25%)

          -  Patients with severe renal disease (i.e., creatinine clearance less than 40 cc/1.73
             m^2)

          -  Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of
             predicted)

          -  Patients with severe hepatic disease (direct bilirubin greater than 3 ug/dl or SGPT
             (serum glutamic-pyruvic transaminase) greater than 500 ug/dl)

          -  Patients with severe personality disorder or mental illness

          -  Patients with a severe infection that on evaluation by the Principal Investigator
             precludes ablative chemotherapy or successful transplantation

          -  Patients with documented HIV positivity

        'High risk' ALL or AML refers to those acute leukemias identified by the presence of
        specific biologic features, which predict high likelihood of failure to conventional
        chemotherapy. As biologic features of high risk disease evolve with improvement of
        conventional chemotherapy, it is not practical to define this indication with any further
        specificity. Therefore, high risk AML/ALL will be determined by the primary physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Krance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosptial</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>January 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 21, 2020</results_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Krance</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>haploidenticalstem cell transplant</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>Non Hodgkins Lymphoma</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Chronic myelogenous leukemia</keyword>
  <keyword>Hemophagocytic lymphohistiocytosis (HLH)</keyword>
  <keyword>Familial hemophagocytic lymphohistiocytosis (FLH)</keyword>
  <keyword>Viral-associated hemophagocytic syndrome (VAHS)</keyword>
  <keyword>X-linked lymphoproliferative disease (XLP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CLINIMACS Device</title>
          <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
        </group>
        <group group_id="P2">
          <title>ISOLEX Device</title>
          <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subsequent transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment - hematopoietic cell product</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who had their donor stem cells processed using the ISOLEX or CliniMACS CD34 Reagent System and started preparative regimen were included in this analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>CLINIMACS Device</title>
          <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
        </group>
        <group group_id="B2">
          <title>ISOLEX Device</title>
          <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="5" upper_limit="13"/>
                    <measurement group_id="B2" value="7" lower_limit="2.5" upper_limit="11"/>
                    <measurement group_id="B3" value="7" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Engraftment Rate After Transplant</title>
        <description>Percentage of participants with hematopoietic engraftment post-transplant. Engraftment is defined as the first day absolute neutrophil counts exceeded 0.5 X 10^9/ml.</description>
        <time_frame>28 days</time_frame>
        <population>A participant is evaluable for engraftment if the participant underwent transplant and either completed 28 days observation or engrafted. Of the 46 participants at baseline, one in CLINIMACS group did not undergo transplant and one in ISOLEX group died 5 days after transplant.Thus, 2 participants were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CLINIMACS Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
          <group group_id="O2">
            <title>ISOLEX Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment Rate After Transplant</title>
          <description>Percentage of participants with hematopoietic engraftment post-transplant. Engraftment is defined as the first day absolute neutrophil counts exceeded 0.5 X 10^9/ml.</description>
          <population>A participant is evaluable for engraftment if the participant underwent transplant and either completed 28 days observation or engrafted. Of the 46 participants at baseline, one in CLINIMACS group did not undergo transplant and one in ISOLEX group died 5 days after transplant.Thus, 2 participants were not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80.5" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="87.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Post BMT Toxicities</title>
        <description>Number of participants who experience organ failure or severe infections (defined as Grade III/IV by NCI CTC for Adverse Events (CTCAE), version 2.0)</description>
        <time_frame>100 Days</time_frame>
        <population>Of the 46 participants at baseline, one participant in CLINIMACS Device group did not undergo haploidentical stem cell transplant and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CLINIMACS Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
          <group group_id="O2">
            <title>ISOLEX Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Early Post BMT Toxicities</title>
          <description>Number of participants who experience organ failure or severe infections (defined as Grade III/IV by NCI CTC for Adverse Events (CTCAE), version 2.0)</description>
          <population>Of the 46 participants at baseline, one participant in CLINIMACS Device group did not undergo haploidentical stem cell transplant and was not included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe GVHD Rate</title>
        <description>Percentage of participants with Grade III/IV acute GVHD. Severe GVHD is defined as Grade III/IV acute GVHD.</description>
        <time_frame>100 Days</time_frame>
        <population>A participant is evaluable for acute GVHD if the participant engrafted and either completed 100 days observation after transplant or experienced acute GVHD. Of the 46 participants at baseline, eight participants in CLINIMACS and five in ISOLEX were not evaluable for acute GVHD and were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CLINIMACS Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
          <group group_id="O2">
            <title>ISOLEX Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Severe GVHD Rate</title>
          <description>Percentage of participants with Grade III/IV acute GVHD. Severe GVHD is defined as Grade III/IV acute GVHD.</description>
          <population>A participant is evaluable for acute GVHD if the participant engrafted and either completed 100 days observation after transplant or experienced acute GVHD. Of the 46 participants at baseline, eight participants in CLINIMACS and five in ISOLEX were not evaluable for acute GVHD and were not included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="4.3" lower_limit="0.1" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Acute GVHD</title>
        <description>Number of participants with acute GVHD graded by the method of Przepiorka et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD</description>
        <time_frame>First 100 Days</time_frame>
        <population>A participant is evaluable for acute GVHD if the participant engrafted and either completed 100 days observation after transplant or experienced acute GVHD. Of the 46 participants at baseline, eight participants in CLINIMACS and five in ISOLEX were not evaluable for acute GVHD and were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CLINIMACS Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
          <group group_id="O2">
            <title>ISOLEX Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Acute GVHD</title>
          <description>Number of participants with acute GVHD graded by the method of Przepiorka et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD</description>
          <population>A participant is evaluable for acute GVHD if the participant engrafted and either completed 100 days observation after transplant or experienced acute GVHD. Of the 46 participants at baseline, eight participants in CLINIMACS and five in ISOLEX were not evaluable for acute GVHD and were not included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Chronic GVHD</title>
        <description>Number of participants with chronic GVHD graded by the method of Przepiorka et al, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3.</description>
        <time_frame>Up to 1 Year</time_frame>
        <population>Patients surviving more than 100 days were evaluable for chronic GvHD. Of the 46 participants at baseline, eight participants in CLINIMACS and six in ISOLEX were not evaluable for chronic GVHD and were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CLINIMACS Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
          <group group_id="O2">
            <title>ISOLEX Device</title>
            <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Chronic GVHD</title>
          <description>Number of participants with chronic GVHD graded by the method of Przepiorka et al, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3.</description>
          <population>Patients surviving more than 100 days were evaluable for chronic GvHD. Of the 46 participants at baseline, eight participants in CLINIMACS and six in ISOLEX were not evaluable for chronic GVHD and were not included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immune Reconstitution</title>
        <description>To evaluate the effect of T-cell depletion by positive selection for CD34 on immune reconstitution, which will be determined from total lymphocyte count, from T and B cell numbers and from T cell subset analyses.</description>
        <time_frame>1 Year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Length of Remission in Patients</title>
        <description>Median length of remission in patients with high risk leukemia treated with myeloablative chemotherapy, radiotherapy and CD34 selected peripheral blood stem cells from haploidentical related donors using Kaplan-Meier method</description>
        <time_frame>1 Year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time participants started preparative regimen to 100 days post transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CLINIMACS Device</title>
          <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
        </group>
        <group group_id="E2">
          <title>ISOLEX Device</title>
          <description>Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
Ara-C: day-8 through day-5
3 g/m2 q 12 hours
Cyclophosphamide: day-7 and day-6
45 mg/kg
Campath-1H: day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
&gt;30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS
Total Body Irradiation: day-4 through day-1
175 cGy x 2 at 24 cGy/min
Stem Cell Infusion: Stem cells are infused on day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE V2</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other: Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>pharyngeal ulcers</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Dysfunction/Failure (clinical)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>SGOT (AST) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-Related Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection/Febrile Neutropenia-Other: HHV6 viremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection(documented clinically or microbiologically)with grade 3 or 4 neutropenia(ANC &lt;1.0 x 10e9/L</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary-Other: Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary-Other: Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary-Other: Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome(ARDS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other: Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other: Mediastinal hematoma after replacing central line.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other: Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE V2</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal Pain or Cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic enlargement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Portal vein flow</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-Related Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection/Febrile Neutropenia -Other: Parainfluenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection(documented clinically or microbiologically)with grade 3 or 4 neutropenia(ANC &lt;1.0 x 10e9/L</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>GGT (Gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>SGOT (AST) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>BUN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Alkalosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pneumonitis/Pulmonary Infiltrates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other: Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert A. Krance</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-824-4661</phone>
      <email>rakrance@txch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

